Prot #QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)

Project: Research project

Project Details

StatusActive
Effective start/end date9/15/209/15/23

Funding

  • Pharmaceutical Research Associates, Inc. (Prot #QBGJ398-302)
  • QED Therapeutics, Inc. (Prot #QBGJ398-302)